Other

Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)

Royalty Pharma Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) decreased by 3.3% to $204.91M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.8%, from $224.62M to $204.91M. Over 5 years (FY 2020 to FY 2025), Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) shows a downward trend with a -8.1% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2020
Last reportedQ1 2026
Metric ID: other_financing_receivable_allowance_for_credit_loss_cum_59aa79

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$358.95M$300.38M$310.80M$261.22M$247.85M$192.23M$115.42M$122.84M$116.92M$146.83M$137.71M$137.04M$167.94M$201.66M$238.12M$224.62M$216.71M$220.69M$211.96M$204.91M
QoQ Change—-16.3%+3.5%-16.0%-5.1%-22.4%-40.0%+6.4%-4.8%+25.6%-6.2%-0.5%+22.5%+20.1%+18.1%-5.7%-3.5%+1.8%-4.0%-3.3%
YoY Change————-31.0%-36.0%-62.9%-53.0%-52.8%-23.6%+19.3%+11.6%+43.6%+37.3%+72.9%+63.9%+29.0%+9.4%-11.0%-8.8%
Range$115.42M – $358.95M
CAGR-11.1%
Avg YoY Growth+0.5%
Median YoY Growth+0.3%
Current Streak2 quarters decline

Frequently Asked Questions

What is Royalty Pharma's financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal)?
Royalty Pharma (RPRX) reported financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal) of $204.91M in Q1 2026.
How has Royalty Pharma's financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal) changed year-over-year?
Royalty Pharma's financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal) decreased by 8.8% year-over-year, from $224.62M to $204.91M.
What is the long-term trend for Royalty Pharma's financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal)?
Over 5 years (2020 to 2025), Royalty Pharma's financing receivable, allowance for credit loss, cumulative adjustment and credit loss expense (reversal) has grown at a -8.1% compound annual growth rate (CAGR), from $323.72M to $211.96M.